Literature DB >> 18684647

Vanilloid receptor TRPV1-mediated phosphorylation of ERK in murine adjuvant arthritis.

Y Chen1, H H Willcockson, J G Valtschanoff.   

Abstract

OBJECTIVE: The vanilloid receptor transient receptor potential vanilloid 1 (TRPV1), expressed by sensory neurons that innervate joints, is implicated in arthritis but the mechanisms are not fully understood. One possibility is that downstream effects of activation of TRPV1 are mediated by the extracellularly-regulated kinase (ERK). ERK is phosphorylated (p-ERK) in sensory neurons in response to noxious stimuli and its inhibition has been found to be antinociceptive in several pain models. We here wanted to ascertain whether TRPV1 may contribute to the pain hypersensitivity and inflammation of arthritis via an ERK-mediated pathway.
METHODS: We used a model of adjuvant-induced arthritis (AIA) of the ankle and investigated the changes in expression of p-ERK in sensory afferent neurons in dorsal root ganglia (DRG) and spinal dorsal horn of TRPV1-knockout (KO) mice, compared to wild-type (WT) mice of the same genetic background, using multiple immunofluorescence.
RESULTS: Two to three weeks after inducing AIA in mice, the number of neurons in DRG and spinal cord that expressed p-ERK was significantly higher on the side of AIA than on the contralateral, vehicle-injected side. The fraction of p-ERK-positive neurons in the DRG that also expressed TRPV1 was increased, indicating that activation of ERK occurred preferentially in TRPV1-positive neurons. Moreover, TRPV1-KO mice had reduced activation of ERK in sensory neurons, compared to WT mice. These changes in expression of p-ERK correlated with changes in pain behavior and joint histopathology: TRPV1-KO mice had reduced nociceptive behavior and severity of arthritis, compared to WT mice.
CONCLUSION: Our results support the idea that activation of ERK in primary afferent neurons is mediated, at least in part, by TRPV1. In the absence of TRPV1, the signs of arthralgia and histopathology in the mouse model of AIA are reduced. We conclude that TRPV1, expressed by neurons in the articular afferent pathway, contributes to the pathogenesis of arthritis via an ERK-mediated pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684647      PMCID: PMC2673950          DOI: 10.1016/j.joca.2008.06.015

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  63 in total

1.  Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract.

Authors:  Sean M Ward; Julia Bayguinov; Kyung-Jong Won; David Grundy; Hans R Berthoud
Journal:  J Comp Neurol       Date:  2003-10-06       Impact factor: 3.215

Review 2.  The MAPK signaling cascade.

Authors:  R Seger; E G Krebs
Journal:  FASEB J       Date:  1995-06       Impact factor: 5.191

3.  Activation of spinal extracellular signaling-regulated kinase-1 and -2 by intraplantar carrageenan in rodents.

Authors:  Alba Galan; J Antonio Lopez-Garcia; Fernando Cervero; Jennifer M A Laird
Journal:  Neurosci Lett       Date:  2002-03-29       Impact factor: 3.046

4.  Activation of Ras is necessary and sufficient for upregulation of vanilloid receptor type 1 in sensory neurons by neurotrophic factors.

Authors:  Romke Bron; Laura J Klesse; Kirti Shah; Luis F Parada; Janet Winter
Journal:  Mol Cell Neurosci       Date:  2003-01       Impact factor: 4.314

5.  p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia.

Authors:  Ru-Rong Ji; Tarek A Samad; Shan-Xue Jin; Raymond Schmoll; Clifford J Woolf
Journal:  Neuron       Date:  2002-09-26       Impact factor: 17.173

6.  Extracellular signaling-regulated kinase-1 and -2 (ERK 1/2) mediate referred hyperalgesia in a murine model of visceral pain.

Authors:  Alba Galan; Fernando Cervero; Jennifer M A Laird
Journal:  Brain Res Mol Brain Res       Date:  2003-08-19

7.  The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain.

Authors:  Katharine M Walker; Laszlo Urban; Stephen J Medhurst; Sadhana Patel; Mohanjit Panesar; Alyson J Fox; Peter McIntyre
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

8.  p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain.

Authors:  Shan-Xue Jin; Zhi-Ye Zhuang; Clifford J Woolf; Ru-Rong Ji
Journal:  J Neurosci       Date:  2003-05-15       Impact factor: 6.167

9.  Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalgesia.

Authors:  Camilla I Svensson; Xiao-Ying Hua; Andrew A Protter; Henry C Powell; Tony L Yaksh
Journal:  Neuroreport       Date:  2003-06-11       Impact factor: 1.837

10.  Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons.

Authors:  Fumimasa Amaya; Kentaro Oh-hashi; Yoshihisa Naruse; Norio Iijima; Masashi Ueda; Goshun Shimosato; Makoto Tominaga; Yoshifumi Tanaka; Masaki Tanaka
Journal:  Brain Res       Date:  2003-02-14       Impact factor: 3.252

View more
  16 in total

1.  IL-6/p-BTK/p-ERK signaling mediates calcium phosphate-induced pruritus.

Authors:  Sunita Keshari; Chien-Lung Chen; Apriska Dewi Sipayung; Ching-Chuan Hsieh; Li-Jen Su; Yun-Ru Chiang; Huan-Cheng Chang; Wu-Chang Yang; Tsung-Hsien Chuang; Chun-Ming Huang
Journal:  FASEB J       Date:  2019-07-31       Impact factor: 5.191

2.  TRPV1 in experimental autoimmune prostatitis.

Authors:  Kenny Roman; Christel Hall; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Prostate       Date:  2019-10-01       Impact factor: 4.104

3.  Effect of genetic deletion of the vanilloid receptor TRPV1 on the expression of Substance P in sensory neurons of mice with adjuvant-induced arthritis.

Authors:  Helen H Willcockson; Yong Chen; Ji Eun Han; Juli G Valtschanoff
Journal:  Neuropeptides       Date:  2010-03-19       Impact factor: 3.286

4.  Increased expression of CGRP in sensory afferents of arthritic mice--effect of genetic deletion of the vanilloid receptor TRPV1.

Authors:  Yong Chen; Helen H Willcockson; Juli G Valtschanoff
Journal:  Neuropeptides       Date:  2008-09-11       Impact factor: 3.286

Review 5.  TRPV1, TRPA1, and TRPM8 channels in inflammation, energy redirection, and water retention: role in chronic inflammatory diseases with an evolutionary perspective.

Authors:  Rainer H Straub
Journal:  J Mol Med (Berl)       Date:  2014-05-29       Impact factor: 4.599

6.  Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways.

Authors:  Zhizheng Zhao; Huiting Fan; Tim Higgins; Jia Qi; Diana Haines; Anna Trivett; Joost J Oppenheim; Hou Wei; Jie Li; Hongsheng Lin; O M Zack Howard
Journal:  Cancer Lett       Date:  2014-09-19       Impact factor: 8.679

7.  Resiniferatoxin (RTX) causes a uniquely protracted musculoskeletal hyperalgesia in mice by activation of TRPV1 receptors.

Authors:  Ramy E Abdelhamid; Katalin J Kovács; Christopher N Honda; Myra G Nunez; Alice A Larson
Journal:  J Pain       Date:  2013-11-01       Impact factor: 5.820

8.  Suppression of TRPV1/TRPM8/P2Y Nociceptors by Withametelin via Downregulating MAPK Signaling in Mouse Model of Vincristine-Induced Neuropathic Pain.

Authors:  Adnan Khan; Bushra Shal; Ashraf Ullah Khan; Rahim Ullah; Muhammad Waleed Baig; Ihsan Ul Haq; Eun Kyoung Seo; Salman Khan
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

9.  Targeting TRPV1 for Body Weight Control using TRPV1(-/-) Mice and Electroacupuncture.

Authors:  Monchanok Choowanthanapakorn; Kung-Wen Lu; Jun Yang; Ching-Liang Hsieh; Yi-Wen Lin
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

10.  Acupuncture Alleviates Colorectal Hypersensitivity and Correlates with the Regulatory Mechanism of TrpV1 and p-ERK.

Authors:  Shao-Jun Wang; Hao-Yan Yang; Guo-Shuang Xu
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-11       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.